cas 154598-52-4, Efavirenz | Articles data

Articles about 154598-52-4Total 40 be found

Article title
Article abstract
Author
Journal number and time
Download

L-743,726 (DMP-266): A novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase
The clinical benefit of the human immunodeficiency virus type 1 (HIV-1) nonnucleoside reverse transcriptase (RT) inhibitors (NNRTIs) is limited by the rapid selection of inhibitor-resistant vital variants. However, it may he possible to enhance the clinical utility of this inhibitor class by deriving compounds that express both high levels of antiviral activity and an augmented pharmacokinetic profile. Accordingly, we developed a new class of NNRTIs, the 1,4-dihydro-2H-3,1-benzoxazin-2-ones. L-743,726 (DMP-266), a member of this class, was chosen for clinical evaluation because of its in vitro properties. The compound was a potent inhibitor of the wild-type HIV-1 RT (K(i) = 2.93 nM) and exhibited a 95% inhibitory concentration of 1.5 nM for the inhibition of HIV-1 replicative spread in cell culture. In addition, L-743,726 was found to be capable of inhibiting, with 95% inhibitory concentrations of ≤1.5 μM, a panel of NNRTI-resistant mutant viruses, each of which expressed a single RT amino acid substitution. Derivation of virus with notably reduced susceptibility to the inhibitor required prolonged cell culture selection and was mediated by a combination of at least two RT amino acid substitutions. Studies of L-743,726 in rats, monkeys, and a chimpanzee demonstrated the compound's potential for good oral bioavailability and pharmacokinetics in humans.
Young,Britcher,Tran,Payne,Lumma,Lyle,Huff,Anderson,Olsen,Carroll,Pettibone,O'Brien,Ball,Balani,Lin,Chen,Schleif,Sardana,Long,et al.
p. 2602 - 2605
(1995)
Read Online

Use of an Ephedrine Alkoxide to Mediate Enantioselective Addition of an Acetylide to a Prochiral Ketone: Asymmetric Synthesis of the Reverse Transcriptase Inhibitor L-743,726.
The asymmetric synthesis of L-743,726 was achieved in six steps with an overall yield of 31 percent.The asymmetry was introduced using a lithiated ephedrine to mediate acetylide addition to a trifluoromethyl ketone with an enantiomeric excess of 96-98 percent.
Thompson, Andrew S.,Corley, Edward G.,Huntington, Martha F.,Grabowski, E. J. J.
p. 8937 - 8940
(1995)
Read Online

Development and Validation of RP-Chiral HPLC Method for Determination of (R)-Enantiomer Excess Content in Efavirenz
A simple, specific, linear, accurate and precise reverse phase chiral HPLC method was developed for the separation of efavirenz enantiomers by using the Lux Amylose-2 column containing amylose tris(5-chloro-2-methyl phenyl carbamate) as a stationary phase. The mobile phase consists of 0.1 % formic acid in water and acetonitrile (55:45, v/v). The flow rate was kept at 1.0 mL/min and the detection wavelength used 252 nm and the column temperature was set at 25 oC. The limit of detection was 0.01 mg/mL and the limit of quantification was 0.04 mg/mL. The linearity calibration curve of (R)-enantiomer was shown well from the range of 0.04 mg/mL to 0.4 mg/mL. The values of the correlation coefficient were 0.999 and 0.999 for (R)-enantiomer and (S)-efavirenz, respectively. The percentage recoveries of (R)-enantiomer from efavirenz drug substance were ranged from 93.5% to 107.5%. The results demonstrated that developed RP-chiral HPLC method was simple, precise, robust and applicable for the estimation of (R)-enantiomer in efavirenz API. This method was validated in as per ICH Q2 (R1) and USP validation of compendial methods .
Ramesh,Devi, Dharmasoth Rama,Srinivas,Radha Krishna,Rajana, Nagaraju,Basavaiah
p. 2208 - 2212
(2020)
Read Online

Efavirenz synthesis method and method for preparing intermediate of efavirenz
The invention discloses an efavirenz synthesis method and a method for preparing an intermediate of efavirenz. The efavirenz synthesis method comprises the following steps: mixing (2S)-2-(2-amino-5-chlorphenyl)-4-cyclopropyl-1, 1, 1-trifluoromethyl-3-butyne-2-ol, methyl tert-butyl ether and a potassium bicarbonate aqueous solution; adding a triphosgene-containing benzene or triphosgene-containingisopropyl ether solution, and reacting until the raw materials disappear; separating liquid, and washing with edible salt water; drying and concentrating the organic phase to obtain a crude product efavirenz; and recrystallizing to obtain the efavirenz. The yield of the product is improved, so that the cost is greatly reduced, and the market competitiveness is improved.
-
Paragraph 0051-0053

(2020/09/02)

METHOD FOR THE MANUFACTURE OF EFAVIRENZ
This invention relates to a method for the manufacture of optically pure (S)-6- chloro-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1 -benzoxazin- 2-one. Specifically, this invention relates to a flow synthesis method for the manufacture of (S)-6-chloro-(cyclopropylethynyl)-1,4-dihydro-4- (trifluoromethyl)-2H-3,1 -benzoxazin-2-one.
-
(2018/09/19)

Eluent tolerance and enantioseparation recovery of chiral packing materials based on chitosan bis(phenylcarbamate)-(n-octyl urea)s for high performance liquid chromatography
The goal of the present work was to study the influence of the swelling of chitosan derivatives on the enantioseparation and the separation performance recovery of chiral stationary phases (CSPs) based on these derivatives. Therefore, six chitosan bis(phenylcarbamate)-(n-octyl urea)s were synthesized, which were coated on macroporous 3-aminopropyl silica gel affording new CSPs. Most of the CSPs demonstrated strong enantioseparation capability for the tested chiral compounds. The swelling capacity of the chitosan bis(phenylcarbamate)-(n-octyl urea)s in ethyl acetate, acetone and tetrahydrofuran (THF) was evaluated. Among the chitosan derivatives, the chitosan bis(3,5-dichlorophenylcarbamate)-(n-octyl urea) polymer showed the highest swelling capacity in ethyl acetate and THF. The polymer-based CSPs could be utilized with pure ethyl acetate and a normal phase containing 70% THF, but was damaged by pure THF. On the other hand, the separation performance of the damaged CSP could be recovered after it was allowed to stand for a period of time. The observations are important for the development and application of polysaccharide derivative-based CSPs.
Wang, Jing,Huang, Shao-Hua,Chen, Wei,Bai, Zheng-Wu
supporting information

(2016/12/02)

Alkynyl Cinchona Catalysts affect Enantioselective Trifluoromethylation for Efavirenz under Metal-Free Conditions
Efavirenz is manufactured worldwide, and its asymmetric synthesis requires a complex organometallic approach, while an organocatalytic approach is far less efficient. The first highly enantioselective approach is disclosed for the synthesis of Efavirenz under nonmetal organocatalysis with up to 93% ee for the Merck intermediate and 91% ee for the Lonsa intermediate using novel alkynyl cinchona catalysts.
Okusu, Satoshi,Hirano, Kazuki,Yasuda, Yoshimasa,Tanaka, Junki,Tokunaga, Etsuko,Fukaya, Haruhiko,Shibata, Norio
p. 5568 - 5571
(2016/11/17)

Synthesis method of chiral cyclopropylacetylenyl tert-alcohol compound
The invention provides a synthesis method of chiral cyclopropylacetylenyl tert-alcohol compound. The optically active propynol compound is obtained through a reaction of chiral amine alcohol or chiral aminodiol as a ligand in the presence of an alkaline regent and salt. The method concretely comprises the following steps: 1, reacting cyclopropyl acetylene with a chiral induction reagent, a chiral auxiliary reagent and zinc halide in an organic solvent in the presence of an alkaline reagent and sulfonate or sulfinate to obtain a first reaction mixture; and 2, reacting the first reaction mixture with 5-chloro-2-aminotrifluorobenzophenone to form (S)-2-amino-5-chloro-alpha-cyclopropylacetylenyl-alpha-trifluoromethylbenzyl alcohol. The method avoids use of an organic zinc reagent and a Grignard reagent, has the advantages of safe production, environmentally-friendly route, low production cost, and high yield and high chiral ee value of the obtained product, and is suitable for industrial production.
-
Paragraph 0119; 0120; 0121; 0122; 0123

(2016/10/09)

waylen apperception HIV reverse transcriptase inhibitors in accordance with the law of the process for the asymmetric synthesis of one-pot synthesis (by machine translation)
The invention relates to a novel one pot method asymmetric synthesis process of a (S)-6-chlorine-4-cylopropyl ethylnen-4-trifluoromethyl-1,4-dihydro-2H-1,3-benzoxazine-2-ketone (Efavirenz) compound, the compound can be used as an reverse transcriptase inhibitor for human immunodeficiency virus (HIV). The invention also relates to a novel aminoalcohol ligand used for the process.
-
Paragraph 0224; 0225; 0226; 0293; 0294; 0295

(2016/10/07)

PROCESS FOR THE PREPARATION OF EFAVIRENZ USING KETON SOLVENTS
Object of the present invention is an improved process for the preparation of Efavirenz, avoiding the distillations of the solvents.
-
Paragraph 082-086

(2016/01/15)

AN IMPROVED PROCESS FOR THE PREPARATION OF A NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR
The present invention relates to an improved process for the preparation of a non-nucleoside reverse transcriptase inhibitor. Specifically, the present invention relates to an improved process for the preparation of Efavirenz of Formula 1. The present invention also relates to a process for the preparation of compound of Formula 2, an intermediate used in the preparation of Efavirenz, wherein X is a halogen atom; X1 is a leaving group.
-
Page/Page column 16

(2015/09/22)

PROCESS FOR PREPARATION OF EFAVIRENZ BY CYCLISATION
The invention disclosed a process for the preparation of the HIV drug Efavirenz, also known as DMP-266, starting from 1,4-dichlorobenzene, and its intermediates.
-
(2012/08/07)

PROCESS FOR PREPARING EFAVIRENZ
The invention disclosed a 4 step process for the preparation of Efavirenz, starting from 1,4-dichlorobenzene, and its intermediates.
-
(2012/06/30)

DMP-266 BY CYCLISATION
Disclosed is a method for the preparation of the HIV drug Efavirenz, also known as DMP-266, starting from 1,4-dichlorobenzene, and its intermediates.
-
(2012/08/07)

Process for the synthesis of cyclic carbamates
The invention is directed to a process for the preparation of a cyclic carbamate starting with a chiral propargylic alcohol and/or a suitable salt thereof, which is reacted with a cyclisation agent selected from phosgene, diphosgene, triphosgene and mixtures thereof, and in that the reaction is carried out in the presence of an aqueous base, and a water-immiscible organic solvent, said organic solvent mainly comprising at least one compound selected from C2-5-alkyl C2-5-carboxylates and mixtures of at least one C2-5-alkyl C2-5-carboxylate with at least one C5-8-alkane. Another aspect of the invention is directed to a process for the synthesis of said cyclic carbamate starting described above, wherein also a process for the preparation of the chiral propargylic alcohol is provided.
-
(2012/05/20)

PROCESS FOR THE SYNTHESIS OF CYCLIC CARBAMATES
The invention is directed to a process for the preparation of a cyclic carbamate starting with o-aminobenzyl alcohol and/or a suitable salt thereof, which is reacted with a cyclisation agent selected from phosgene, diphosgene, triphosgene and mixtures thereof, and in that the reaction carried out in the presence of an aqueous base, and a water-immiscible organic solvent, said organic solvent mainly comprising at least one compound selected from C2-5-alkyl C2-5-carboxylates and mixtures of at least one C2-5-alkyl C2-5-carboxylate with at least one C5-8-alkane.
-
Page/Page column 27-28

(2012/05/04)

PROCESS FOR THE SYNTHESIS OF CYCLIC CARBAMATES
The invention is directed to a process for the preparation of a cyclic carbamate starting with a chiral propargylic alcohol and/or a suitable salt thereof, which is reacted with a cyclisation agent selected from phosgene, diphosgene, triphosgene and mixtures thereof, and in that the reaction is carried out in the presence of an aqueous base, and a water-immiscible organic solvent, said organic solvent mainly comprising at least one compound selected from C2-5-alkyl C2-5-carboxylates and mixtures of at least one C2-5-alkyl C2-5-carboxylate with at least one C5-8-alkane. Another aspect of the invention is directed to a process for the synthesis of said cyclic carbamate starting described above, wherein also a process for the preparation of the chiral propargylic alcohol is provided.
-
Page/Page column 32-33

(2012/05/04)

PROCESS FOR PREPARATION OF EFAVIRENZ
An improved process for Efavirenz, which has several advantages over reported methods like low cost, high yield, better optical purity and industrial feasibility.
-
Page/Page column 2-3

(2012/05/07)

PROCESS FOR THE SYNTHESIS OF CHIRAL PROPARGYLIC ALCOHOLS
A process for the synthesis of chiral propargylic alcohols.
-
Page/Page column 16-17

(2012/05/04)

Process for the synthesis of cyclic carbamates
The invention is directed to a process for the preparation of a cyclic carbamate starting with o-aminobenzyl alcohol and/or a suitable salt thereof, which is reacted with a cyclisation agent selected from phosgene, diphosgene, triphosgene and mixtures thereof, and in that the reaction is carried out in the presence of an aqueous base, and a water-immiscible organic solvent, said organic solvent mainly comprising at least one compound selected from C2-5-alkyl C2-5-carboxylates and mixtures of at least one C2-5-alkyl C2-5-carboxylate with at least one C5-8-alkane.
-
Page/Page column 12

(2012/05/04)

A new synthetic approach to efavirenz through enantioselective trifluoromethylation by using the ruppert-prakash reagent
The organocatalyzed asymmetric synthesis of efavirenz was achieved in five steps from a commercially available substrate through the operationally simple, enantioselective trifluoromethylation of an alkynyl ketone by using the Ruppert-Prakash reagent. The present method provides the first example of the enantioselective synthesis of efavirenz by using a direct trifluoromethylation approach. The organocatalyzed asymmetric synthesis of efavirenz was achieved in five steps from a commercially available substrate through the operationally simple, enantioselective trifluoromethylation of an alkynyl ketone by using the Ruppert-Prakash reagent. The present method provides the first example of the enantioselective synthesis of efavirenz by using a direct trifluoromethylation approach.
Kawai, Hiroyuki,Kitayama, Takashi,Tokunaga, Etsuko,Shibata, Norio
supporting information; experimental part
p. 5959 - 5961
(2011/12/03)

AN IMPROVED PROCESS FOR PREPARATION OF EFAVIRENZ
An improved process for Efavirenz, which has several advantages over reported methods like low cost, high yield, better optical purity and industrial feasibility (A).
-
Page/Page column 6

(2011/02/24)

METHODS OF MAKING EFAVIRENZ AND INTERMEDIATES THEREOF
The present invention provides a process for the preparation of Efavirenz. A compound of Formula 1 may be prepared by a process comprising cyclizing, in the presence of a first base, a compound of Formula 5 with a haloformate of Formula 6. Other processes are also provided as well as novel compounds prepared by and used in such processes.
-
Page/Page column 14

(2011/02/18)

PROCESS FOR THE SYNTHESIS OF CHIRAL CYCLIC CARBAMATES
The invention is directed to a process for the preparation of a chiral cyclic carbamate of formula (I) and/or mirror image, and/or a salt thereof, from the corresponding o-aminobenzyl alcohol and/or salts thereof.
-
Page/Page column 9

(2010/11/03)

PROCESS FOR THE PREPARATION OF EFAVIRENZ
The present invention is directed to a process for the preparation of Efavirenz, (4S)-6-chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-1,4-dihydro-2H-3,1-benzoxazin-2-one, of formula (I) comprising reacting the intermediate of formula (II) [0045] as a free base or a salt thereof, with diphosgene (TCMCF, trichlormethylchloroformate) Cl3CO-COCl in an organic solvent or in a biphasic medium comprised of an organic solvent and water, preferably but not mandatorily in the presence of a weak base in an amount sufficient to neutralise the reaction mixture or in an up to 30% molar excess of such amount.
-
Page/Page column 8-9

(2010/08/09)

NOVEL PROCESS
A simple, cost-effective process for preparation of efavirenz of formula (I) comprising reacting a solution of 5-chloro-α-(cyclopropylethynyl)-2-amino-α-trifluoromethyl) benzene methanol of formula (II) in an organic solvent with triphosgene in the presence of an inorganic base at a temperature range -5 °C to 25 °C, adding water and isolating compound of formula (I).
-
Page/Page column 16; 17

(2010/04/25)

PROCESS FOR THE PREPARATION OF EFAVIRENZ
The present invention relates to a process for the preparation of Efavirenz (Formula I), wherein triphosgene is used as a cyclizing agent.
-
Page/Page column 4; 5

(2009/12/05)

Synthesis of a benzoxazinone
The present invention provides novel methods for the synthesis of (S)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one of formula (III) which is useful as a human immunodeficiency virus (HIV) reverse transcriptase inhibitor.
-
Page/Page column 4

(2008/06/13)

NOVEL POLYMORPHS OF EFAVIRENZ
The present invention relates to novel amorphous and crystalline forms of efavirenz, processes for their preparation and pharmaceutical compositions containing them. In accordance with the present invention efavirenz crude is dissolved in acetone at 25°C - 30°C, the solution is slowly added to water for 30 minutes at 0°C - 5°C, stirred for 1 hour at the same temperature, the separated solid is filtered, washed with water and dried at 55°C - 60°C for 5 hours to give amorphous efavirenz.
-
Page/Page column 5-6

(2008/06/13)

EFFICIENT SYNTHESIS OF A 1,4-DIHYDRO-2H-3,1-BENZOXAZIN-2-ONE
-
-
Page/Page column 18

(2010/02/11)

Method and compositions for identifying anti-HIV therapeutic compounds
Methods are provided for identifying anti-HIV therapeutic compounds substituted with carboxyl ester or phosphonate ester groups. Libraries of such compounds are screened optionally using the novel enzyme GS-7340 Ester Hydrolase. Compositions and methods relating to GS-7340 Ester Hydrolase also are provided.
-
(2008/06/13)

EFFICIENT ENANTIOSELECTIVE ADDITION REACTION USING AN ORGANOZINC REAGENT
Preparation of an alcohol of formula (I), or its enantiomer, comprises: (a) slowly adding a dialkylzinc (II), optionally in a solvent, to a chiral additive (III) (optionally mixed with a second chiral additive (IV)), in a solvent under an inert atmosphere at -78 to 50[deg]C, to form a chiral zinc complex ; (b) adding (IV) (if not added in (a)) and heating to 10-70[deg]C; (c) mixing the product from (b) with an organometallic reagent of formula R6M (V) in a solvent at -20 to 60[deg]C to form a chiral organozinc complex; and (d) mixing the solution from (c) with a ketone of formula (VI), optionally dissolved in a solvent, under an inert atmosphere at 20 to 60[deg]C for about 1-72 hours: A = 1-6C alkyl, 2-6C alkenyl or 2-6C alkynyl, optionally substituted with 1 or 2 Q, or Ph, biphenyl or naphthyl, optionally substituted with 1-4 R1, R2, R3 or R4; Q = halo, CF3, CN, NO2, NH2, NH(1-6C alkyl), N(1-6C alkyl)2, CONH2, CONH(1-6C alkyl), CON(1-6C alkyl)2, NHCONH2, NHCONH(16C alkyl), NHCON(1-6C alkyl)2, CO2-(1-6C alkyl), 3-7C cycloalkyl or 1-6C alkoxy; R1-R4 = Q, 1-6C alkyl, 2-6C alkenyl or 2-6C alkynyl, where 1-6C alkyl is optionally substituted with Ph, biphenyl or naphthyl (optionally substituted with 1-6C alkyl, 1-6C alkoxy, NO2 or halo); R5 = H; 1-6C alkyl, 2-6C alkenyl or 2-6C alkynyl, optionally substituted with 1 or 2 Q; or 1-4C perfluoroalkyl; R6 = 1-6C alkyl, 2-6C alkenyl or 2-6C alkynyl, optionally substituted with 1 or 2 Q; M = Li, Na, K, Zn, MgX1, CuX1 or B(X1)2; X1 = Cl, Br, I, F or CF3SO2.
-
Page 32 - 33

(2010/02/07)

Crystalline Efavirenz
The potent reverse transcriptase inhibitor Efavirenz is produced in crystalline form. Crystalline Efavirenz exists in several physical forms which are-designated Forms 1, 2, 3 and 4, and are characterized by x-ray powder diffraction and differential scanning calorimetry. Pharmaceutical compositions and methods are useful for the treatment of the human immunodeficiency virus (HIV).
-
(2008/06/13)

Method and compositions for identifying anti-HIV therapeutic compounds
Methods are provided for identifying anti-HIV therapeutic compounds substituted with carboxyl ester or phosphonate ester groups. Libraries of such compounds are screened optionally using the novel enzyme GS-7340 Ester Hydrolase. Compositions and methods relating to GS-7340 Ester Hydrolase also are provided.
-
(2008/06/13)

PROCESS FOR ENHANCING THE OPTICAL PURITY OF 2R- 1-HYDROXY- 1-TRIFLUOROMETHYL- 3-CYCLOPROPYLPROPYN-2YL] -4-CHLOROANILINE
-
-
Page/Page column 16-17

(2008/06/13)

Practical synthesis of benzoxazinones useful as HIV reverse transcriptase inhibitors
The present invention describes novel methods for the synthesis of benzoxazinone compounds which are useful as human immunodeficiency virus (HIV) reverse transcriptase inhibitors. The benzoxazinone of the formula: is particularly effective in the treatment of HIV.
-
Page column 23

(2010/01/30)

Synthesis of cyclopropylacetylene
The present invention relates generally to novel methods for the synthesis of cyclopropylacetylene which is a reagent in the asymmetric synthesis of (S)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one which is a useful human immunodeficiency virus (HIV) reverse transcriptase inhibitor.
-
(2008/06/13)

Asymmetric synthesis of benzoxazinones
The present invention provides novel methods for the asymmetric synthesis of (S)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one of formula (VI-i) STR1 which is useful as a human immunodeficiency virus (HIV) reverse transcriptase inhibitor.
-
(2008/06/13)

Asymmetric synthesis of benzoxazinones
The present invention provides novel methods for the asymmetric synthesis of (S)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one of formula (VI-i) STR1 which is useful as a human immunodeficiency virus (HIV) reverse transcriptase inhibitor.
-
(2008/06/13)

Practical asymmetric synthesis of Efavirenz (DMP 266), an HIV-1 reverse transcriptase inhibitor
A highly enantioselective and practical synthesis of the HIV-1 reverse transcriptase inhibitor efavirenz (1) is described. The synthesis proceeds in 62% overall yield in seven steps from 4-chloroaniline (6) to give efavirenz (1) in excellent chemical and optical purity. A novel, enantioselective addition of Li-cyclopropyl acetylide (4a) to p-methoxybenzyl-protected ketoaniline 3a mediated by (1R,2S)-N-pyrrolidinylnorephedrine lithium alkoxide (5a) establishes the stereogenic center in the target with a remarkable level of stereocontrol.
Pierce, Michael E.,Parsons Jr., Rodney L.,Radesca, Lilian A.,Lo, Young S.,Silverman, Stuart,Moore, James R.,Islam, Qamrul,Choudhury, Anusuya,Fortunak, Joseph M. D.,Nguyen, Dieu,Luo, Chi,Morgan, Susan J.,Davis, Wayne P.,Confalone, Pat N.,Chen, Cheng-Yi,Tillyer, Richard D.,Frey, Lisa,Tan, Lushi,Xu, Feng,Zhao, Dalian,Thompson, Andrew S.,Corley, Edward G.,Grabowski, Edward J. J.,Reamer, Robert,Reider, Paul J.
p. 8536 - 8543
(2007/10/03)

Chemical Properties

Appearance/Colour :white to slightly pink crystalline powder
Melting Point: 139-141 °C
Boiling Point: 340.6 °C at 760 mmHg
Flash Point:159.8 °C
Density: 1.53 g/cm³
Solubility:DMSO: soluble15mg/mL, clear
Storage Temp.:-20°C Freezer
Vapor Pressure: 8.53E-05mmHg at 25°C
Refractive Index: 1.58
PKA: 10.2(at 25℃)
Merck: 14,3521
PSA: 38.33000
LogP: 4.21110

Global suppliers and manufacturers of 154598-52-4total 183 suppliers on LookChem

Company Name
Business Type
Min Order
FOB Price
Main Products
Contact

Shanghai Send Pharmaceutical Technology Co., Ltd.
Business Type:Lab/Research institutions
Min Order:1 Gram
FOB Price:No Data
Main Products:28
Country:

Dayang Chem (Hangzhou) Co.,Ltd.
Business Type:Lab/Research institutions
Min Order:1 Kilogram
FOB Price:USD $ 3.0-3.0 / Kilogram
Main Products:994
Country:

Sinoway Industrial Co., Ltd.
Business Type:Trading Company
Min Order:1 Kilogram
FOB Price:USD $ 350.0-350.0 / Kilogram
Main Products:105
Country:

Xi'an Xszo Chem Co., Ltd.
Business Type:Manufacturers
Min Order:1 Gram
FOB Price:USD $ 0.1-0.1 / Gram
Main Products:108
Country:

Chemwill Asia Co., Ltd.
Business Type:Manufacturers
Min Order:5 Kiloliter
FOB Price:USD $ 1.2-5.0 / Kiloliter
Main Products:56
Country:

Hebei yanxi chemical co.,LTD.
Business Type:Trading Company
Min Order:5 Gram
FOB Price:USD $ 500.0-500.0 / Gram
Main Products:84
Country:

Hubei DiBo chemical co., LTD
Business Type:Other
Min Order:25 Kilogram
FOB Price:USD $ 2.0-3.0 / Kilogram
Main Products:34
Country:

Hebei Nengqian Chemical Import and Export Co., LTD
Business Type:Trading Company
Min Order:1 Kilogram
FOB Price:USD $ 1.0-10.0 / Kilogram
Main Products:165
Country:

Henan Tianfu Chemical Co., Ltd.
Business Type:Lab/Research institutions
Min Order:1 Kilogram
FOB Price:No Data
Main Products:67
Country:

Zhuozhou Wenxi import and Export Co., Ltd
Business Type:Trading Company
Min Order:1 Kilogram
FOB Price:USD $ 139.0-210.0 / Kilogram
Main Products:1
Country:

Hubei Vanz Pharm Co.,Ltd
Business Type:Trading Company
Min Order:1 Kilogram
FOB Price:No Data
Main Products:86
Country:

Henan Sinotech Import&Export Corporation
Business Type:Other
Min Order:1 Metric Ton
FOB Price:USD $ 1.0-2.0 / Metric Ton
Main Products:21
Country:

Hubei Langyou International Trading Co., Ltd
Business Type:Other
Min Order:100 Gram
FOB Price:No Data
Main Products:15
Country:

HANWAYS CHEMPHARM CO.,LIMITED
Business Type:Trading Company
Min Order:1 Kilogram
FOB Price:USD $ 20.0-40.0 / Kilogram
Main Products:85
Country:

Shanghai Upbio Tech Co.,Ltd
Business Type:Lab/Research institutions
Min Order:10 Gram
FOB Price:No Data
Main Products:30
Country:

Hangzhou Huarong Pharm Co., Ltd.
Business Type:Lab/Research institutions
Min Order:1 Kilogram
FOB Price:USD $ 1.0-2.0 / Kilogram
Main Products:65
Country:

Baoji Guokang Healthchem co.,ltd
Business Type:Trading Company
Min Order:1 Kilogram
FOB Price:USD $ 75.0-90.0 / Kilogram
Main Products:41
Country:

Qingdao Beluga Import and Export Co., LTD
Business Type:Lab/Research institutions
Min Order:1 Gram
FOB Price:No Data
Main Products:117
Country:

Shandong Hanjiang Chemical Co., Ltd.
Business Type:Lab/Research institutions
Min Order:1 Kilogram
FOB Price:No Data
Main Products:78
Country:

Wuhan Wonda Pharm Limited
Business Type:Lab/Research institutions
Min Order:10 Gram
FOB Price:No Data
Main Products:22
Country:

Post a RFQ

Cas No.:

Product Name:

Quantity:

Email:

Company name:

Valid Period:

Detailed Requirements:

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

What can I do for you?
Get Best Price

Get Best Price for 154598-52-4

Article Database

154598-52-4

Articles about 154598-52-4Total 40 be found

More Articles about upstream products of 154598-52-4

More Articles about downstream products of 154598-52-4

Chemical Properties

Appearance/Colour :white to slightly pink crystalline powder

Melting Point: 139-141 °C

Boiling Point: 340.6 °C at 760 mmHg

Flash Point:159.8 °C

Density: 1.53 g/cm³

Solubility:DMSO: soluble15mg/mL, clear

Storage Temp.:-20°C Freezer

Vapor Pressure: 8.53E-05mmHg at 25°C

Refractive Index: 1.58

PKA: 10.2(at 25℃)

Merck: 14,3521

PSA: 38.33000

LogP: 4.21110

Global suppliers and manufacturers of 154598-52-4total 183 suppliers on LookChem

Article Database

154598-52-4

Articles about 154598-52-4Total 40 be found

More Articles about upstream products of 154598-52-4

More Articles about downstream products of 154598-52-4

Chemical Properties

Appearance/Colour :white to slightly pink crystalline powder

Melting Point: 139-141 °C

Boiling Point: 340.6 °C at 760 mmHg

Flash Point:159.8 °C

Density: 1.53 g/cm3

Solubility:DMSO: soluble15mg/mL, clear

Storage Temp.:-20°C Freezer

Vapor Pressure: 8.53E-05mmHg at 25°C

Refractive Index: 1.58

PKA: 10.2(at 25℃)

Merck: 14,3521

PSA: 38.33000

LogP: 4.21110

Global suppliers and manufacturers of 154598-52-4total 183 suppliers on LookChem

Density: 1.53 g/cm³